Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 91

1.

A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer.

De Visschere PJL, Standaert C, Fütterer JJ, Villeirs GM, Panebianco V, Walz J, Maurer T, Hadaschik BA, Lecouvet FE, Giannarini G, Fanti S.

Eur Urol Oncol. 2019 Feb;2(1):47-76. doi: 10.1016/j.euo.2018.09.010. Epub 2018 Oct 24. Review.

PMID:
30929846
2.

[Systemic treatment of metastatic tumors of the upper urinary tract].

Darr C, Hadaschik BA, Tschirdewahn S.

Urologe A. 2019 Jan;58(1):30-33. doi: 10.1007/s00120-018-0835-8. Review. German.

PMID:
30617528
3.

68Ga-PSMA-11 PET/CT in prostate cancer local recurrence: impact of early images and parametric analysis.

Sachpekidis C, Pan L, Hadaschik BA, Kopka K, Haberkorn U, Dimitrakopoulou-Strauss A.

Am J Nucl Med Mol Imaging. 2018 Oct 20;8(5):351-359. eCollection 2018.

4.

Multiparametric MRI and MRI/TRUS Fusion Guided Biopsy for the Diagnosis of Prostate Cancer.

Schütz V, Kesch C, Dieffenbacher S, Bonekamp D, Hadaschik BA, Hohenfellner M, Radtke JP.

Adv Exp Med Biol. 2018;1096:87-98. doi: 10.1007/978-3-319-99286-0_5.

PMID:
30324349
5.

Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.

Saad F, Cella D, Basch E, Hadaschik BA, Mainwaring PN, Oudard S, Graff JN, McQuarrie K, Li S, Hudgens S, Lawson J, Lopez-Gitlitz A, Yu MK, Smith MR, Small EJ.

Lancet Oncol. 2018 Oct;19(10):1404-1416. doi: 10.1016/S1470-2045(18)30456-X. Epub 2018 Sep 10.

PMID:
30213449
6.

Radiomic Machine Learning for Characterization of Prostate Lesions with MRI: Comparison to ADC Values.

Bonekamp D, Kohl S, Wiesenfarth M, Schelb P, Radtke JP, Götz M, Kickingereder P, Yaqubi K, Hitthaler B, Gählert N, Kuder TA, Deister F, Freitag M, Hohenfellner M, Hadaschik BA, Schlemmer HP, Maier-Hein KH.

Radiology. 2018 Oct;289(1):128-137. doi: 10.1148/radiol.2018173064. Epub 2018 Jul 31.

PMID:
30063191
7.

Twelve-month prostate volume reduction after MRI-guided transurethral ultrasound ablation of the prostate.

Bonekamp D, Wolf MB, Roethke MC, Pahernik S, Hadaschik BA, Hatiboglu G, Kuru TH, Popeneciu IV, Chin JL, Billia M, Relle J, Hafron J, Nandalur KR, Staruch RM, Burtnyk M, Hohenfellner M, Schlemmer HP.

Eur Radiol. 2019 Jan;29(1):299-308. doi: 10.1007/s00330-018-5584-y. Epub 2018 Jun 25.

PMID:
29943185
8.

Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas.

Reis H, van der Vos KE, Niedworok C, Herold T, Módos O, Szendrői A, Hager T, Ingenwerth M, Vis DJ, Behrendt MA, de Jong J, van der Heijden MS, Peyronnet B, Mathieu R, Wiesweg M, Ablat J, Okon K, Tolkach Y, Keresztes D, Nagy N, Bremmer F, Gaisa NT, Chlosta P, Kriegsmann J, Kovalszky I, Timar J, Kristiansen G, Radzun HJ, Knüchel R, Schuler M, Black PC, Rübben H, Hadaschik BA, Schmid KW, van Rhijn BWG, Nyirády P, Szarvas T.

Int J Cancer. 2018 Apr 19. doi: 10.1002/ijc.31547. [Epub ahead of print]

9.

MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.

Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budäus L, Hellawell G, Hindley RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Virdi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik BA, Ruffion A, Hu JC, Margolis D, Crouzet S, Klotz L, Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani S, Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM; PRECISION Study Group Collaborators.

N Engl J Med. 2018 May 10;378(19):1767-1777. doi: 10.1056/NEJMoa1801993. Epub 2018 Mar 18.

10.

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.

Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ; SPARTAN Investigators.

N Engl J Med. 2018 Apr 12;378(15):1408-1418. doi: 10.1056/NEJMoa1715546. Epub 2018 Feb 8.

11.

68Ga-PSMA PET/CT in the evaluation of bone metastases in prostate cancer.

Sachpekidis C, Bäumer P, Kopka K, Hadaschik BA, Hohenfellner M, Kopp-Schneider A, Haberkorn U, Dimitrakopoulou-Strauss A.

Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):904-912. doi: 10.1007/s00259-018-3936-0. Epub 2018 Jan 23.

PMID:
29362859
12.

Multiparametric-MRI-Guided Biopsy in the Era of Precision Medicine.

Bergero MA, Martínez PF, Radtke JP, Hadaschik BA.

Arch Esp Urol. 2017 Dec;70(10):833-844. Review. Spanish, English.

PMID:
29205162
13.

Multiparametric MRI fusion-guided biopsy for the diagnosis of prostate cancer.

Kesch C, Schütz V, Dieffenbacher S, Bonekamp D, Hadaschik BA, Hohenfellner M, Radtke JP.

Curr Opin Urol. 2018 Mar;28(2):172-177. doi: 10.1097/MOU.0000000000000461.

PMID:
29083999
14.

Investigation of the halo-artifact in 68Ga-PSMA-11-PET/MRI.

Heußer T, Mann P, Rank CM, Schäfer M, Dimitrakopoulou-Strauss A, Schlemmer HP, Hadaschik BA, Kopka K, Bachert P, Kachelrieß M, Freitag MT.

PLoS One. 2017 Aug 17;12(8):e0183329. doi: 10.1371/journal.pone.0183329. eCollection 2017.

15.

Transcriptome Wide Analysis of Magnetic Resonance Imaging-targeted Biopsy and Matching Surgical Specimens from High-risk Prostate Cancer Patients Treated with Radical Prostatectomy: The Target Must Be Hit.

Radtke JP, Takhar M, Bonekamp D, Kesch C, Erho N, du Plessis M, Buerki C, Ong K, Davicioni E, Hohenfellner M, Hadaschik BA.

Eur Urol Focus. 2018 Jul;4(4):540-546. doi: 10.1016/j.euf.2017.01.005. Epub 2017 Jan 26.

PMID:
28753844
16.

Why Targeting of PSMA Is a Valuable Addition to the Management of Castration-Resistant Prostate Cancer: The Urologist's Point of View.

Hadaschik BA, Boegemann M.

J Nucl Med. 2017 Aug;58(8):1207-1209. doi: 10.2967/jnumed.117.194753. Epub 2017 May 18. No abstract available.

17.

Intraindividual Comparison of 18F-PSMA-1007 PET/CT, Multiparametric MRI, and Radical Prostatectomy Specimens in Patients with Primary Prostate Cancer: A Retrospective, Proof-of-Concept Study.

Kesch C, Vinsensia M, Radtke JP, Schlemmer HP, Heller M, Ellert E, Holland-Letz T, Duensing S, Grabe N, Afshar-Oromieh A, Wieczorek K, Schäfer M, Neels OC, Cardinale J, Kratochwil C, Hohenfellner M, Kopka K, Haberkorn U, Hadaschik BA, Giesel FL.

J Nucl Med. 2017 Nov;58(11):1805-1810. doi: 10.2967/jnumed.116.189233. Epub 2017 May 4. Erratum in: J Nucl Med. 2019 Apr;60(4):554.

18.

Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.

Radtke JP, Wiesenfarth M, Kesch C, Freitag MT, Alt CD, Celik K, Distler F, Roth W, Wieczorek K, Stock C, Duensing S, Roethke MC, Teber D, Schlemmer HP, Hohenfellner M, Bonekamp D, Hadaschik BA.

Eur Urol. 2017 Dec;72(6):888-896. doi: 10.1016/j.eururo.2017.03.039. Epub 2017 Apr 8.

PMID:
28400169
19.

The Value of PSA Density in Combination with PI-RADS™ for the Accuracy of Prostate Cancer Prediction.

Distler FA, Radtke JP, Bonekamp D, Kesch C, Schlemmer HP, Wieczorek K, Kirchner M, Pahernik S, Hohenfellner M, Hadaschik BA.

J Urol. 2017 Sep;198(3):575-582. doi: 10.1016/j.juro.2017.03.130. Epub 2017 Mar 31.

PMID:
28373135
20.

TOP: Prospective Evaluation of a Volume Based, Computer Assisted Method for Transperineal Optimized Prostate Biopsy.

Kesch C, Radtke JP, Popeneciu IV, Gasch C, Dieffenbacher SC, Klein T, Schlemmer HP, Wieczorek K, Zogal P, Hohenfellner M, Sakas G, Hadaschik BA.

Urol Int. 2017;99(2):149-155. doi: 10.1159/000458764. Epub 2017 Mar 28.

PMID:
28346914

Supplemental Content

Loading ...
Support Center